For several years, we have been committed to treating chronic venous disease, partnering with health care professionals 👩⚕️🧑⚕️. Venous disease is one of the most common diseases. Varicose veins are present in 25%-33% of female and 10%-40% of male adults. This summer, we’re back 🚀🔥 with a new season of our awareness campaign. Are you ready to be onboard in this Final Call for chronic venous disease? Help us 🗣️ spread the word and share our Facebook and Instagram campaigns? Check our final call video and visit our chronic venous disease section 👉 https://lnkd.in/ecKCRE4F #ChronicVenousDisease #CVD #WeAreServier #MovedByYou
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
Obtenir l’itinéraire
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
🚨 In patients with dyslipidemia, 64% have hypertension and 25% have diabetes. Among these patients, 25.6% have uncontrolled hypertension and 23% have uncontrolled diabetes. 🌐 Tackling these interconnected health issues is essential for improving global health outcomes. Let's work together toward better management and prevention! 🤝 At Servier, we adhere to a holistic approach in treating cardiometabolic and venous diseases (CMVD). Let's be #AsOne for better patient outcomes and tailored solutions. 🔗 For more information, visit servier.com #ASONE #CMVD #CardiovascularDiseases #Diabetes #VenousDiseases
-
-
🚨 At the beginning of the summer, we proposed a challenge to our employees: to take 1 billion steps 🏃♀️🏃♂️ for the Serious Fun association, in order to finance the medical stay of several children suffering from cancer. 🔥🚀 The challenge was met! Over 3,000 employees took part, 79 teams were formed and over 1 billion steps were taken! Congratulations 👏 to all our employees, who are committed to improving patients’ lives! #commitment #patient #WeAreServier #MovedByYou
-
-
Every year, Mécénat Servier launches its "Joint Initiatives" call for projects open to all our sites worldwide 🌍🌏🌎. This provides an opportunity for local teams to identify large-scale projects of general interest, enabling all employees to get involved through skills-based sponsorship missions. This year, Mécénat Servier will support 💪 the nonprofit organization Imagine le Monde in Ivory Coast 🇨🇮 and the organization Life Project 4 Youth (LP4Y) in Indonesia 🇮🇩. Congratulation to all the teams 🚀🔥 committed to solidarity! Learn more about the selected projects 👉 https://lnkd.in/ejjy8YsX #MecenatServier #solidarity #association #education Servier Afrique de l'Ouest et du Centre Servier Indonesia
-
❤️🩺 In today's world, cardiometabolic and venous diseases (CMVD) present a major challenge. At Servier, we're committed to going beyond just treating symptoms. 💊➕ Our portfolio of products and innovative "beyond-the-pill" solutions enhance patient control and adherence, ultimately leading to better care. 🤝 Join us in this mission to rewrite the story of CMVD care. Together, as health care professionals, patients, and Servier, we can make a significant impact. 🌟 Let's be AS ONE in our journey towards improved patient health and well-being. #ASONE #CMVD #CardiovascularDiseases #Diabetes #VenousDiseases
-
Servier is delighted to announce that, as a company with an international footprint, especially in China, we have joined the “Comité France Chine” co-funded by Mouvement des Entreprises de France and co-headed by Jean-Louis Lemierre and Jean-Paul Agon. This institution gathers French companies active in France and in China, on a long-term manner, working together to develop in China and to promote franco-chinese cooperation. Historically present in China since 1979, Servier is proud to count on 1000 collaborators in Beijing and in our plant in Tianjin. We would like to thank Sybille DUBOIS-FONTAINE and her team for their warm welcome and we expect very much from this partnership which will lead to strengthen our relationship with China.
-
-
🔈 Exploring the societal impact of health innovations: watch the full replay of #THRPTX's second panel discussion! Our esteemed panelists Prof. Dipak Kalra, Sandrine Bourguignon, Prof. Hugues de Th��, and Prof. David Edwards engaged in a two-part discussion: 1️⃣ Societal and patient expectations regarding innovation 2️⃣ How society is responding to new challenges posed by innovation Key topics included digital health solutions, accessibility and affordability of treatments, and balancing innovation with regulatory frameworks. 👉 https://lnkd.in/e5xNQ4VJ 🔎 The first Therapeutic Innovation Summit (THRPTX) took place on 18 June 2024 at our R&D Institute in Paris-Saclay, focusing on bringing together over 200 global experts to shape the horizons of an innovative therapeutic future in #oncology. Let’s continue to keep this momentum going and create together new hopes for the patient journey with the return of THRPTX in 2026! #WeAreServier #MovedByYou
-
💪 Our teams mobilize to enhance awareness and control of arterial hypertension around the world. In Portugal 🇵🇹, where 40% of adults suffer from hypertension, Servier Portugal launched the Mission 70/26 initiative in February 2023. This project, in partnership with the Portuguese Society of Hypertension, aims to achieve 70% control of hypertension among patients in primary care by 2026. The initiative has seen significant engagement, with over 10,120 healthcare professionals 👩⚕️🧑⚕️ registered by May 2024. According to Frederic Bengold, General Manager of Servier Portugal, 🗣️ “Charter 70/23, launched in Slovakia in 2019, enhances hypertension adherence using behavioral economics. Defined by experts, its success is now spreading across Europe, including a great adoption by Servier Portugal.” From the starting control point of 52.8% in 2023 and April 2024, the Portuguese Society of Hypertension (SPH) presented the results of the last semester: 60% of control regarding the hypertensive patients followed by the primary care! Congratulations 👏 to the teams involved in this initiative! Read more about this initiative on servier.com 👉 https://lnkd.in/eGA8TiZq #patient #health #WeAreServier #MovedByYou
-
According to the World Health Organization, brain tumors account for around 2% of all adult cancers and 1.9% of all childhood cancers. Gliomas represent about 20% of all brain and CNS tumors. In line with the #Servier2030 ambition, our aim is to become an innovative player focused on hard-to-treat cancers. We develop treatments 🔬 for cancer patients, with a particular focus on digestive cancers, glioma or brain tumors, hematological cancers, and pediatric cancers. Recently, we had the pleasure of speaking 🗣️ with Maya Duvillard, a patient with oligodendroglioma, who tells us about her disease journey. 🎥 Watch her inspiring story on our Instagram account and get her perspectives on the fight against cancer 👉 https://lnkd.in/e4mSA-As You can also find Maya @cmayaduvillard on Instagram. #Glioma #BrainTumor #MovedByYou
-
📣 In the first issue of Insights by Servier, we highlight the start-up Palm Therapeutics, which has joined the FAST Fall cohort of the California Life Sciences (CLS) program, an initiative that supports innovative biotech start-ups in California. 💪 The FAST program provides extensive coaching, helping start-ups refine their business strategies and prepare for successful fundraising. 🙌 At Servier, we sponsor start-ups for the FAST program, further enhancing the collaborative efforts in life sciences and biotechnology. Read the entire article 👉 https://lnkd.in/gmvpqRcg #WeAreServier #InsightsByServier #incubator
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn